5.465  -0.195 (-3.45%)		12-15 15:59
Open: 5.6 High: 5.72 Volume: 290,317		Pre. Close: 5.66 Low: 5.3 Market Cap: 376(M)

Short term
Mid term
Targets	6-month :	7.84	1-year :	9.16
Resists	First :	6.71	Second :	7.84
Pivot price	5.68
Supports	First :	5.13	Second :	4.15
MAs	MA(5) :	5.68	MA(20) :	5.62
	MA(100) :	3.5	MA(250) :	0
MACD	MACD :	0.1	Signal :	0.2
%K %D	K(14,3) :	35.2	D(3) :	40.4
RSI	RSI(14): 51.5
52-week	High :	6.71	Low :	0.87

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PEPG ] has closed above bottom band by 33.7%. Bollinger Bands are 11% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.73 - 5.77	5.77 - 5.79
Low:	5.22 - 5.27	5.27 - 5.3
Close:	5.41 - 5.47	5.47 - 5.52

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Thu, 11 Dec 2025
Bronstein, Gewirtz & Grossman, LLC Is Investigating PepGen Inc. (PEPG) And Encourages Stockholders to Connect - ACCESS Newswire

Wed, 10 Dec 2025
How Much Upside is Left in PepGen (PEPG)? Wall Street Analysts Think 75.44% - Yahoo Finance

Tue, 09 Dec 2025
PepGen (Nasdaq: PEPG) awards option to new Chief Business and Legal Officer under Rule 5635(c)(4) - Stock Titan

Tue, 09 Dec 2025
PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Tue, 09 Dec 2025
PepGen (NASDAQ:PEPG) Targets Next-Gen Treatment Pathways In Biotech - Kalkine Media

Tue, 09 Dec 2025
PepGen Inc. Appoints New Chief Business Officer - The Globe and Mail

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	69 (M)
Shares Float	40 (M)
Held by Insiders	0.1 (%)
Held by Institutions	91.7 (%)
Shares Short	2,300 (K)
Shares Short P.Month	2,320 (K)

EPS	-2.82
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.36
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-34.1 %
Return on Equity (ttm)	-62.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.41
Qtrly Earnings Growth	0 %
Operating Cash Flow	-85 (M)
Levered Free Cash Flow	-52 (M)

PE Ratio	-1.94
PEG Ratio	0
Price to Book value	2.3
Price to Sales	0
Price to Cash Flow	-4.41

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.